Blueprint Medicines CorpNASDAQ:BPMC
- LAST PRICE103.8700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 103.8700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BPMC |
|---|---|---|
| 09:32 ET | 1954 | 105.04 |
| 09:36 ET | 495 | 104.7 |
| 09:39 ET | 1440 | 105.11 |
| 09:41 ET | 400 | 105.3899 |
| 09:43 ET | 100 | 105.41 |
| 09:48 ET | 143 | 105.225 |
| 09:50 ET | 100 | 105.235 |
| 09:52 ET | 1280 | 105.55 |
| 09:56 ET | 588 | 105.315 |
| 09:57 ET | 2462 | 105.12 |
| 09:59 ET | 439 | 105.73 |
| 10:03 ET | 1100 | 105.67 |
| 10:08 ET | 300 | 105.41 |
| 10:10 ET | 665 | 105.41 |
| 10:12 ET | 1100 | 105 |
| 10:19 ET | 338 | 105.145 |
| 10:21 ET | 200 | 105.2 |
| 10:24 ET | 100 | 105.055 |
| 10:26 ET | 100 | 105.165 |
| 10:32 ET | 100 | 105.13 |
| 10:33 ET | 178 | 105.153 |
| 10:35 ET | 1901 | 105.29 |
| 10:37 ET | 2378 | 105.3 |
| 10:39 ET | 1500 | 105.5 |
| 10:42 ET | 100 | 105.395 |
| 10:44 ET | 100 | 105.33 |
| 10:46 ET | 450 | 105.39 |
| 10:48 ET | 600 | 105.27 |
| 10:50 ET | 200 | 105.12 |
| 10:51 ET | 100 | 105.185 |
| 10:53 ET | 300 | 105.18 |
| 10:55 ET | 300 | 105.2 |
| 11:02 ET | 200 | 105.2 |
| 11:08 ET | 100 | 105.17 |
| 11:13 ET | 222 | 105.1 |
| 11:18 ET | 3128 | 105.205 |
| 11:20 ET | 310 | 105 |
| 11:22 ET | 136 | 105.155 |
| 11:27 ET | 1000 | 104.64 |
| 11:29 ET | 100 | 104.735 |
| 11:31 ET | 1200 | 104.735 |
| 11:36 ET | 1400 | 104.55 |
| 11:38 ET | 500 | 104.65 |
| 11:40 ET | 100 | 104.62 |
| 11:42 ET | 1300 | 104.605 |
| 11:44 ET | 400 | 105.05 |
| 11:47 ET | 1239 | 105.21 |
| 11:49 ET | 211 | 105.17 |
| 11:54 ET | 843 | 105.185 |
| 11:56 ET | 100 | 105.195 |
| 11:58 ET | 100 | 105.205 |
| 12:02 ET | 1300 | 105.225 |
| 12:03 ET | 600 | 105.22 |
| 12:05 ET | 1799 | 105.2 |
| 12:07 ET | 100 | 105.21 |
| 12:09 ET | 1982 | 105.2 |
| 12:12 ET | 100 | 105.195 |
| 12:14 ET | 200 | 105.2 |
| 12:16 ET | 400 | 105.2 |
| 12:21 ET | 100 | 105.225 |
| 12:25 ET | 300 | 105.55 |
| 12:27 ET | 971 | 105.535 |
| 12:30 ET | 1200 | 105.62 |
| 12:32 ET | 526 | 105.55 |
| 12:36 ET | 1000 | 105.44 |
| 12:38 ET | 158 | 105.4 |
| 12:39 ET | 300 | 105.23 |
| 12:41 ET | 200 | 105.29 |
| 12:45 ET | 300 | 105.14 |
| 12:48 ET | 200 | 105.19 |
| 12:50 ET | 100 | 105.09 |
| 12:52 ET | 1100 | 105.235 |
| 12:54 ET | 700 | 105.275 |
| 12:56 ET | 100 | 105.26 |
| 12:57 ET | 300 | 105.3731 |
| 12:59 ET | 200 | 105.28 |
| 01:01 ET | 800 | 105.285 |
| 01:03 ET | 400 | 105.28 |
| 01:06 ET | 2355 | 105.43 |
| 01:08 ET | 928 | 105.4 |
| 01:10 ET | 400 | 105.27 |
| 01:12 ET | 670 | 105.077 |
| 01:14 ET | 100 | 105.077 |
| 01:15 ET | 500 | 105.215 |
| 01:17 ET | 1943 | 105.235 |
| 01:19 ET | 100 | 105.12 |
| 01:21 ET | 500 | 105.45 |
| 01:24 ET | 400 | 105.21 |
| 01:26 ET | 500 | 105.08 |
| 01:28 ET | 1420 | 105.15 |
| 01:32 ET | 800 | 105.24 |
| 01:33 ET | 300 | 105.41 |
| 01:35 ET | 240 | 105.61 |
| 01:39 ET | 300 | 106 |
| 01:42 ET | 67580 | 106.85 |
| 01:44 ET | 51146 | 107.02 |
| 01:46 ET | 28126 | 107.375 |
| 01:48 ET | 3160 | 107.39 |
| 01:50 ET | 1794 | 107.175 |
| 01:51 ET | 1191 | 107.3778 |
| 01:53 ET | 13598 | 106.69 |
| 01:55 ET | 7309 | 106.4401 |
| 01:57 ET | 3104 | 106.4999 |
| 02:00 ET | 288 | 106.48 |
| 02:02 ET | 1657 | 106.54 |
| 02:04 ET | 3288 | 106.62 |
| 02:06 ET | 1000 | 107.05 |
| 02:08 ET | 856 | 106.9996 |
| 02:09 ET | 1200 | 107 |
| 02:11 ET | 774 | 106.71 |
| 02:13 ET | 1050 | 106.82 |
| 02:15 ET | 823 | 106.5 |
| 02:18 ET | 500 | 106.69 |
| 02:20 ET | 450 | 106.8675 |
| 02:22 ET | 665 | 106.72 |
| 02:24 ET | 5870 | 106.65 |
| 02:26 ET | 1072 | 106.4 |
| 02:27 ET | 1549 | 106.54 |
| 02:29 ET | 616 | 106.53 |
| 02:31 ET | 681 | 106.515 |
| 02:33 ET | 385 | 106.51 |
| 02:36 ET | 280 | 106.505 |
| 02:38 ET | 1857 | 106.47 |
| 02:40 ET | 1100 | 106.505 |
| 02:42 ET | 1200 | 106.47 |
| 02:44 ET | 2300 | 105.95 |
| 02:45 ET | 300 | 105.945 |
| 02:47 ET | 236 | 105.88 |
| 02:51 ET | 300 | 105.76 |
| 02:54 ET | 200 | 105.785 |
| 02:56 ET | 280 | 105.64 |
| 02:58 ET | 200 | 105.485 |
| 03:00 ET | 300 | 105.34 |
| 03:03 ET | 1920 | 105.25 |
| 03:05 ET | 700 | 105.3425 |
| 03:07 ET | 1100 | 105.42 |
| 03:09 ET | 1000 | 105.57 |
| 03:12 ET | 1327 | 105.485 |
| 03:16 ET | 2225 | 105.67 |
| 03:18 ET | 306 | 105.685 |
| 03:20 ET | 1000 | 105.15 |
| 03:21 ET | 5043 | 105.24 |
| 03:23 ET | 100 | 105.24 |
| 03:25 ET | 300 | 105.26 |
| 03:27 ET | 300 | 105.1 |
| 03:30 ET | 1005 | 105.02 |
| 03:32 ET | 1987 | 105.14 |
| 03:34 ET | 246 | 105.09 |
| 03:36 ET | 4244 | 105.21 |
| 03:38 ET | 500 | 105.055 |
| 03:39 ET | 800 | 105.14 |
| 03:41 ET | 500 | 104.99 |
| 03:43 ET | 700 | 104.85 |
| 03:45 ET | 2180 | 104.925 |
| 03:48 ET | 500 | 104.81 |
| 03:50 ET | 1691 | 104.66 |
| 03:52 ET | 3965 | 104.505 |
| 03:54 ET | 5606 | 104.34 |
| 03:56 ET | 9411 | 104.455 |
| 03:57 ET | 64585 | 103.8888 |
| 03:59 ET | 32333 | 103.87 |
Yesterday
Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC), from 7 hours ago by Dow Jones
7 hours ago by Dow JonesAt Present The Schall Law Firm Is Conducting Investigations Into Potential Violations Of Securities Laws For The Advantage Of Blueprint Medicines Corporation (NASDAQ:BPMC) Investors, from 7 hours ago by Dow Jones
7 hours ago by Dow Jones
Jun 13, 2024
Jun 12, 2024
Jun 11, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Blueprint Medicines Corp | 6.6B | -21.5x | --- |
Legend Biotech Corp | 7.7B | -15.9x | --- |
Ascendis Pharma A/S | 7.4B | -13.1x | --- |
Revolution Medicines Inc | 6.4B | -9.9x | --- |
Cytokinetics Inc | 6.3B | -9.8x | --- |
Intra-Cellular Therapies Inc | 7.2B | -59.8x | --- |
Company Information
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Contact Information
- Headquarters
- 45 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-374-7580
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jeffrey Albers
- President, Chief Executive Officer, Director
- Kathryn Haviland
- Chief Financial Officer
- Michael Landsittel
- President - Research and Development
- Fouad Namouni
- Chief Operating Officer
- Christina Rossi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.6B |
|---|---|
Revenue (TTM) | $282.2M |
Shares Outstanding | 62.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-4.82 |
Book Value | $2.14 |
P/E Ratio | -21.5x |
Price/Sales (TTM) | 23.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -94.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
